Clorox reported fourth-quarter and fiscal-year 2026 results after the U.S. close on Monday, August 3, 2026, and the release turned the earlier setup article into a real post-earnings reset. The company said fourth-quarter net sales decreased 2% to USD 1.95 billion, organic sales declined 12%, gross margin fell 520 basis points to 41.3%, and diluted EPS dropped 50% to USD 1.34.
That sounds weak on its face, but the useful options lesson is more specific than “defensive staples name misses.” Clorox also used the release to frame fiscal 2027 as the year after the ERP unwind, with net sales expected to be up 13% to 14%, organic sales expected to increase about 3.5% to 4.5%, and adjusted EPS expected to be between USD 5.70 and USD 6.00. For options traders, that changes the live question from whether the ERP transition was still distorting fiscal 2026 into whether the market is willing to price a cleaner recovery story now that the transition year is in the books.
The release also gave traders a more detailed bridge for the weak quarter. Clorox said the ERP-related shipment comparison and GOJO inventory step-up each reduced gross margin by about 150 basis points. That matters because it helps separate structural business questions from temporary or acquisition-related comparison effects. The stock now has to trade on whether investors believe those headwinds really are fading rather than on whether the company can keep explaining the same transition again.
This article is for market commentary and options education only. This is not financial advice. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure, the guide to how earnings affect options prices and implied volatility, the explainer on implied volatility (IV) in options trading: what it is and why it matters, and the primer on risk management in options trading: position sizing and probability.
What Clorox actually reported
The most important confirmed facts from the August 3, 2026 release were:
- Fourth-quarter net sales decreased 2% to USD 1.95 billion.
- Fourth-quarter organic sales declined 12%.
- Fourth-quarter gross margin decreased 520 basis points to 41.3%.
- Fourth-quarter diluted EPS decreased 50% to USD 1.34.
- Fiscal-year 2026 net sales decreased 5% to USD 6.72 billion.
- Fiscal-year 2026 organic sales decreased 8%.
- Fiscal-year 2026 adjusted EPS decreased 28% to USD 5.53.
- Management said the ERP-related shipment comparison reduced adjusted EPS by about 90 cents for fiscal 2026.
- For fiscal 2027, Clorox expects net sales up 13% to 14%, organic sales up about 3.5% to 4.5%, and adjusted EPS between USD 5.70 and USD 6.00.
Those details matter because they clarify what changed and what did not. The weak quarter was real. But the company is also explicitly asking the market to treat fiscal 2026 as the trough year created by ERP timing, inventory distortions, and integration costs rather than as the new steady state for the business.
Why this matters for options traders
The pre-event setup centered on whether Clorox could convince the market that ERP disruption was temporary. The live-results phase is a little different. The market now has both the final transition-year damage and the first formal recovery frame for fiscal 2027.
That changes the options lesson in three ways.
First, CLX is no longer only an earnings-miss or earnings-beat event. It is now a credibility event around normalization. If traders believe the ERP drag is rolling off and the FY2027 guidance is realistic, the post-earnings reset can look different from the quarter’s headline declines.
Second, the GOJO contribution matters because it changes how investors read the top line. Clorox said fiscal 2027 net sales should benefit from about 9.5 points related to GOJO. That means traders need to look past the headline sales rebound and ask how much of the improvement is acquisition-driven versus organic.
Third, CLX remains a lower-beta name where options premium is often about the size of the information reset rather than about a pure momentum chase. The market is trying to price whether the company has finally moved from an ERP clean-up story into a more stable operating story.
Common misunderstandings and caveats
A bad quarter means the recovery case is dead
No. The quarter was weak, but management paired it with a more explicit FY2027 normalization frame. The real question is whether investors trust that bridge, not whether the transition year looked messy.
Recovery guidance means the risk is gone
No. Guidance is management’s outlook, not proof. Traders still have to watch whether volume, margin, and execution actually improve enough to support the higher 2027 frame.
Staples earnings are too quiet to matter for options
No. Even lower-beta names can produce meaningful repricing when a transition story moves from explanation into evidence. That is especially true when the market has to decide whether one difficult year was temporary or structural.
Bottom line
Clorox’s August 3, 2026 report matters because it turned an ERP-transition setup into a confirmed post-results reset. Fourth-quarter net sales fell to USD 1.95 billion, organic sales fell 12%, gross margin dropped to 41.3%, and diluted EPS fell to USD 1.34. At the same time, management told the market to look ahead to a fiscal 2027 rebound in sales, organic growth, and adjusted EPS.
For options traders, the cleanest lesson is not that Clorox had a weak quarter. It is that the stock now sits between two narratives: the documented damage from the ERP unwind and the market’s willingness, or refusal, to believe the normalization frame management just laid out. That is the tension that should matter more than a one-line headline reaction.
This is not financial advice. Options trading involves risk and is not suitable for all investors.
Sources
- U.S. SEC, The Clorox Company Current Report on Form 8-K dated August 3, 2026 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/21076/000002107626000028/clx-20260803.htm - U.S. SEC, The Clorox Company Exhibit 99.1 press release dated August 3, 2026 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/21076/000002107626000028/ex991-pressreleasedatedaug.htm - The Clorox Company Investor Relations, “Clorox Reports Q3 Fiscal Year 2026 Results, Updates Outlook” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Reports-Q3-Fiscal-Year-2026-Results-Updates-Outlook/default.aspx - The Clorox Company Investor Relations, “Clorox Completes Acquisition of GOJO Industries, Makers of Purell” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Completes-Acquisition-of-GOJO-Industries-Makers-of-Purell/default.aspx
